MISSISSAUGA, ONTARIO (TSX VENTURE: RX) today released a summary of its financial results for the first quarter 2008. For the three months ending March 31, 2008, sales decreased by 4.9% from $302,840 in quarter one 2007 to $287,997 in quarter one 2008. The company incurred a loss of ($74,067) in quarter one 2008 compared to a loss of ($29,416) in quarter one 2007. This loss is predominantly due to higher operating expenses leading up to the launch of Ciprofloxacin Injection which was first shipped in May 2008 and lower sales of Protect-It� in quarter one 2008 as compared to quarter one 2007.

Total working capital has decreased by approximately 9% from $1,097,489 on December 31, 2007 to $1,002,858 on March 31, 2008. Cash and cash equivalents account for 83% of working capital as of March 31, 2008.

Full details of 2008 quarter one results and Financial Statements and Management's Discussion & Analysis will be posted on sedar.com on May 30, 2008.

At the request of the Ontario Securities Commission, BioSyent is also re-filing the Certificates of the President and Chief Executive Officer and of the Chief Financial Officer of the Company in respect of its annual filings for the year ended December 31, 2007, which certificates were previously filed. The refiling of these Certificates is necessary due to the use of outdated forms in the previously filed Certificates. The Company is also refiling its annual MD&A to reflect such revised annual certification and reference to the new certification is contained in Section 11 of the annual MD&A, which is the only section of the MD&A that has been changed.

BioSyent Inc. continues to concentrate on its pharmaceutical strategy to source products that have been successfully developed and proven to be safe and effective; manage these products through the regulatory process and product registration (approval); and once approved, market these products in Canada. These pharmaceuticals will compete in both the branded and generic market segments and will not require further product development investment other than regulatory costs.

BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences pharmaceutical products and markets these products in Canada. Wholly owned BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy business marketing bio and health friendly non-chemical insecticides. BioSyent common shares are listed for trading on the TSX Venture Exchange (TSXV) under the symbol RX.

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of the same.

Contacts: BioSyent Inc. Rene C. Goehrum President and CEO (905) 206-0013 (905) 206-1413 (FAX) Email: rgoehrum@biosyent.com Website: www.biosyent.com

Biosyent (TSXV:RX)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Biosyent Charts.
Biosyent (TSXV:RX)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Biosyent Charts.